Flagship taps startup to hunt for obesity drugs that might interest Pfizer

BioPharma Dive June 12, 2024
Delilah Alvarado

The venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates that Pfizer can choose to advance under a partnership it struck with Flagship last year.

Dive Brief:

• Flagship Pioneering will partner with biotechnology startup ProFound Therapeutics to search for promising drug candidates for obesity that Pfizer, under a deal struck with Flagship last year, may later choose to advance.
• The collaboration between Flagship and ProFound, which the venture firm founded in 2022, is the first drug-hunting effort started through the alliance Flagship and Pfizer formed in July. At the time, both Flagship and Pfizer said they would invest $50 million to develop 10 drug candidates that Pfizer would have an option to later license...

Today's Sponsors

Today's Sponsor